-
-
DICLOFENAC SODIUM (Generic for MOTRIN ARTHRITIS PAIN)
- QTY 100
- 1 %
- Gel
- Near 77381
DICLOFENAC (dye KLOE fen ak) treats joint pain caused by arthritis. It works by decreasing inflammation. It belongs to a group of medications called NSAIDs.
Change Location
Set Price Drop Alert for:
DICLOFENAC SODIUM (Generic for MOTRIN ARTHRITIS PAIN)
- QTY 100
- 1 %
- Gel
What does Supply mean?
If your selected quantity is intended to last longer than one month, please recheck the price using the 3-months supply option. In some cases, the estimated drug price may vary depending on the supply duration.
More Ways to Save On:
DICLOFENAC SODIUM (Generic for MOTRIN ARTHRITIS PAIN)
- QTY 100
- 1 %
- Gel
You may find alternative ways to save with this medication. Talk to your pharmacist about the potential option(s) noted below.
Change Form
Medicine Chest
DICLOFENAC SODIUM (Generic for MOTRIN ARTHRITIS PAIN) Lifestyle Interactions
-
Rifampin 600mg, Lyophilisate for solution for injection
• Interaction: Alcohol• Severity: Major• Notes for Consumers: Do not drink alcohol while taking this medication. Drinking alcohol while taking this medication increases the risk of liver injury. Contact your care team right away if you experience right upper belly pain, loss of appetite, nausea, light-colored stool, dark yellow or brown urine, yellowing skin or eyes, or unusual weakness or fatigue.• Notes for Professionals: Rifampin is associated with dose-related hepatoxicity. Daily use of alcohol while receiving rifampin increases the risk of drug-induced hepatitis. Liver-function tests should be conducted prior to and every 2-4 weeks during treatment in patients who consume alcohol routinely while receiving rifampin therapy. -
Rifampin 600mg, Lyophilisate for solution for injection
• Interaction: Cannabis• Severity: Major• Notes for Consumers: Discuss cannabis use with your care team. The effects of cannabis may be altered if used with your medication.• Notes for Professionals: Advise patients to avoid cannabis use during rifampin treatment. Concomitant use may decrease the concentration of some cannabinoids and alter their effects. The cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are CYP3A substrates and rifampin is a strong CYP3A inducer. Concomitant use of a cannabinoid product containing THC and CBD at an approximate 1:1 ratio with rifampin decreased THC, 11-OH-THC, and CBD peak exposures by 36%, 87%, and 52% respectively.
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.
